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Abstract
Optimal medication should be characterized by good bioavailability, rapid onset of action, a long period of therapeutic activity, with 
preserved high safety profile and the lowest possible risk of side effects. Therefore, in addition to traditional drug administration 
routes, such as oral or injection, novel methods for drug applications, for example in the form of a nasal application have been 
developed. Because of the anatomy of the nose, drugs administered intranasally can be rapidly absorbed and, depending on the 
nature of the active substance, may act locally on the mucosa or can have a significant systemic effect. Most nasal drugs are 
developed in the form of solution administered as aerosol. In some cases, these solutions are thixotropic. They are able to change 
their physical properties under agitation to facilitate supply of the drug and its adhesion to the mucosa. Intranasal corticosteroids 
represent the mainstay of treatment for any form of chronic allergic rhinitis (AR) and moderate to severe periodic AR, especially 
with impaired nasal obstruction and frequent occurrence of symptoms. The article discusses the rheological properties of intra-
nasal corticosteroids, their role in therapy and efficacy in the everyday clinical practice.
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Streszczenie
Optymalny lek powinien charakteryzować się bardzo dobrą przyswajalnością, szybkim początkiem działania, długim okresem 
aktywności terapeutycznej, przy zachowanym wysokim profilu bezpieczeństwa i najniższym możliwym ryzyku działań niepożąda-
nych. Dlatego oprócz tradycyjnych dróg podawania leków, jak doustna czy iniekcyjna, wprowadza się nowe metody ich podaży, 
na przykład w postaci aplikacji donosowej. Ze względu na warunki anatomiczne nosa leki podawane donosowo mogą być szybko 
wchłaniane i w zależności od charakteru substancji czynnej działać miejscowo na błonę śluzową lub mieć wpływ ogólnoustrojowy. 
Preparaty donosowe najczęściej mają postać roztworu aplikowanego w postaci aerozolu. W niektórych przypadkach roztwory 
te mają charakter tiksotropowy, czyli zmieniają swe własności fizyczne pod wpływem wstrząsania, co ułatwia podaż leku i jego 
przyleganie do śluzówki. Glikokortykosteroidy donosowe są podstawą leczenia każdej postaci przewlekłego alergicznego nieżytu 
nosa (ANN) oraz umiarkowanej i ciężkiej postaci okresowego ANN, zwłaszcza przy upośledzeniu drożności nosa i częstym wystę-
powaniu objawów. W artykule omówiono właściwości reologiczne glikokortykosteroidów donosowych oraz ich miejsce w terapii 
i skutecznośc w codziennej praktyce klinicznej.
Słowa kluczowe: aerozol donosowy, tiksotropia, adhezja, glikokortykosteroidy donosowe
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Introduction
Intranasal administration of the drugs could 
be used either as an application route of topic 
drugs used in patients with upper airways diseases 
or as an alternative route of absorption of systemic 
drugs with low bioavailability or high molecular 
weight, such as proteins, peptides or steroids. To 
date many drugs have been successfully used in-
tranasally, including drugs constricting the vessels 
of nasal mucosa (a-mimetics — e.g. adrenaline, 
xylomethazoline, cholinolytics — ipratropium bro-
mide), mucolytics (mesna), antihistaminic drugs 
(azelastine), glucocorticosteroids (e.g. budesonide, 
beclomethasone, fluticasone, mometasone), chro-
mones (e.g. sodium cromoglicate, nedocromil), 
antibiotics (mupirocin, neomycin). The systemic 
drugs which could be administered intranasally 
include hormones (e.g. calcitonin, insulin, and 
vasopressin) and antihypertensive agents (e.g. 
hydralazine, propranolol, nifedipine). Another 
group constitute immunomodulatory drugs e.g. 
vaccines (e.g. anti-influenza) and allergens-con-
taining extracts used in specific immunotherapy. 
To note, some of intranasally administered drugs 
could penetrate into central nervous system (CNS) 
passing the blood-brain barrier (e.g. apomorphine, 
buprenorphine, cocaine).
Pharmacological aspects of intranasal therapy
Relatively large nasal mucosal surface area 
and its extensive vascularization enable effective 
absorption, which in practice leads to fast thera-
peutical effect. Due to bypassing of portal circula-
tion the absorbed substances avoid the first-pass 
effect and metabolism in liver. Additionally, the 
enzymatic activity of nasal mucosa is lower as of 
gastrointestinal tract mucosa and this enhances the 
bioavailability of proteins and peptide. The lower 
risk of overdose in comparison to other routes of 
administration is also of importance, and in case 
of need to remove the excess of a drug the nasal 
cavities could be irrigated. Moreover, easy and 
non-invasive way of administration of the drugs 
improves the compliance and patient’s adherence. 
It should be underlined, that, as all the other 
administration routes, nasal application of the 
drugs have some limitations. Speed of absorption 
in different parts of nasal cavity varies. Natural 
sneeze reflex could eliminate some portion of the 
drug and estimation of the amount of removed 
drug is usually impossible. Intranasally admin-
istered agents should not irritate the mucosa. 
Another natural mechanism of eliminating of the 
drugs is mucociliary clearance. The single dose of 
applied drug should not be too large to not disturb 
the physiological functions of nose cavity, and 
thus the volume of single application should not 
exceed 25–200 µl. Different abnormalities of nasal 
mucosa could impair the absorption, as well as 
the administration of the substances of molecular 
weight of more than 1kDa [1]. 
Anatomy and physiology of the nose
Nose is the first section of the upper respira-
tory tract. It contributes to gas exchange though 
air transportation, which is warmed, moisturized 
and cleared during inspiration. According to ex-
cessive vascularization and innervation the nose 
also plays a role in reflexive immune reactions, 
intending to eliminate external harmful factors 
[2]. Nose is the organ of smell. Intrinsic surface of 
the nose cavities is covered by mucosa, stretching 
away on nose-lacrimal ducts, maxillary, ethmoid-
al, sphenoidal and frontal paranasal sinuses as 
well as nasal part of pharynx. The mucosa of nose 
consists of multilayered ciliated epithelium with 
cilia, which are moving with frequency of up to 
1000 movements per minute [3]. The mucociliary 
clearance speed is estimated of about 5 mm/min. 
It means that half-time of the clearance of mucosa 
takes app. 15 minutes [4]. The mucosal surface is 
in folds and additionally enlarged owing to pres-
ence of microvilli, which number is estimated of 
app. 400 on each cell. The total mucosal surface 
area is estimated of app. 150−160 cm2. As com-
pared to the mucosa in other organs and tracts, the 
nasal mucosa in relatively thin and basal layer is 
more porous. In physiological situation the nasal 
mucosa produces app. 160 mL mucus discharge 
daily. It is estimated that number of mucus glands 
in nose cavities amount app. 105. The mucus lay-
er of the thickness of about 5 µm is two-layered 
with external gel layer as well as internal layer 
of sol. The mucus consists of water in 95%, 2% 
of mucine, 1% — proteins such as immunoglob-
ulins, albumins, lysozyme and lactoferrin 1% 
— the salts and lipids below of 1%. Stability and 
permeability of mucus layer is based on surface 
tension, connected to the presence of phospholip-
ids. These heterogeneous microparticles are built 
of peptic core and incorporated oligosaccharide 
chains. Verdugo et al. [5] proposed the model 
in which randomly tangled macromolecules are 
connected forming the loose net. The inflamma-
tory cells, e.g. neutrophils and eosinophils could 
alter the physicochemical properties of mucus. 
Disintegration of cells of contained DNA cause 
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the binding of glycoproteins of mucus discharge. 
Mentioned changes in the mucus structure could 
lead to changes of its physicochemical properties, 
which subsequently could negatively impact on 
absorption of drugs built of proteins and peptide.
In allergic rhinitis, after allergen exposure, 
specific IgE antibodies bound to the high affin-
ity IgE receptor (FcxRI) on mast cells are cross 
linked by allergen which leads to degranulation 
of mast cells and release of preformed mediators 
(including histamine) and synthesis of several 
pro-inflammatory cytokines and chemokines. 
Symptoms of acute allergic reaction including 
itching and sneezing are followed by nasal ob-
struction which is associated with edema of 
nasal mucosa, influx of proinflammatory cells, 
mucus production due to stimulation of glan-
dular cells and extravasation from capillaries. 
Influx of immunocompetent cells (eosinophils, 
basophils, lymphocytes T) is led by chemokines 
(RANTES, eotaxin, Il-8). Other proinflammatory 
cytokines: Il-1 and TNF-a induce expression of 
selectins and VCAM-1 which improve the migra-
tion of cells. Several cytotoxic proteins released 
from eosinophils and basophils lead to tissue 
damage, decrease in mucociliary clearance, and 
desquamation of the epithelium. In conclusion 
patomechanisms involved in chronic inflamma-
tion in allergic rhinitis are complex and include 
activation and migration of inflammatory cells, 
vascular dilatation, increase and changes of glan-
dular activity, activation of nerve endings, onset 
of a neurogenic inflammation and morphological-
ly demonstrable alterations in the nasal mucosa.
Intranasal drugs application
The particles of a drug, administered by pres-
sure application are deposited in target location, 
which is nasal mucosa surface covered by mucus. 
They are further spontaneously spread on mucosa 
surface according to the concentration gradient, e.g. 
diffusion. The migration of the particles through 
the mucosa depends on its properties of mucus 
layer, such as size of mucus bowls, as well as the 
properties of applied substance which are as follow:
—  the size of particle (smaller particles move 
faster as compare to larger ones),
—  dissociation rate — nondissociated sub-
stances diffuse faster than substances with 
negative charge,
—  solubility in lipids — with more solubility 
the diffusion of particles is easier.
Of note is that quite fast diffusion of relatively 
large particles, enclosed by liposomes, niosomes 
or microspheres has been observed. Some of the 
drugs are transported actively, due to mechanism 
of transcytosis, with the use of transport proteins 
and intracellular channels [6, 7].
The separate aspect is delivering the intrana-
sally administered drugs to CNS. Olfactory area 
located in the upper part of nasal cavity is the only 
part of CNS directly contacting with external en-
vironment. The particles of the drug deposited on 
this area migrate through the mucosa according 
to the mechanism already mentioned or could be 
transferred using axonal transport by projections 
of the olfactory neurons to the olfactory bulb 
placed in the basal part of the telencephalon. This 
is the way the active substance could reach CNS 
bypassing the blood-brain barrier [4].
Intranasal drug as a fluid under mechanics rules
The suspension is the physical system of at 
least two substances, in which the solid bodies 
particles (e.g. drug) are dispersed in the external 
phase, usually liquid (diluter). The homogeneity 
of the suspension depends on the size of dis-
persed particles and viscosity of diluter. In case 
that density of dispersed phase is higher than di-
luter the dispersed particles could go down which 
is called sedimentation. In this phenomenon 
the particles of the fluid are able to freely move 
relative to each other. Forces of friction between 
moving particles or layers created by themare 
called viscosity. The viscosity depends on small 
distances between liquid particles as well as con-
necting cohesive forces. The viscosity is greater 
with greater cohesive forces and greater friction 
resistance within the liquid. The coagulation of 
the liquid means the flow of liquid layers moving 
relative to each, and decreasing of the flow speed 
is called the speed of coagulation. 
According to the viscosity the fluids could 
be divided to so-called newtonian liquids (with 
stable viscosity) and so-called non newtonian liq-
uids (with changeable viscosity). The latter among 
others encompass the suspensions. The viscosity 
of non newtonian liquids, called structural vis-
cosity, depends not only on the size and shape of 
dispersed particles but also on their volume and 
electric charge. In some non newtonian liquids the 
changers of internal structure could be observed, 
caused by energy delivered by coagulation forces. 
Thixotropy or “liquid memory” describes the rela-
tion between viscosity of such liquid end duration 
of acting of coagulation forces, for example the 
decreasing of the viscosity of thixotropic liquid 
under intensive blending and shaking. This pro-
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cess is reversible and after some time the previous 
viscosity of the fluid is restored [8].
On the molecular level thixotropy is connect-
ed with presence of the forces of intermolecular 
interactions. Relative moving of the atoms and 
particles closer to each other results in the chang-
es of distribution of the electrons in their struc-
ture and in inducing mild electromagnetic field. 
Within this field van der Waals forces, hydrogen 
bonds, interactions as well as dipole-dipole in-
teractions could be detected. Spatial structure of 
the substance is based on the shape of particles 
and magnitude of intermolecular interactions. 
In liquids prone to coagulation the acting of 
the forces leads to breaking the weaker phys-
ical bonds and structural disintegration of the 
medium. This is multistep process, progressing 
proportionally to the coagulation time and mag-
nitude of coagulative forces. During this process 
there is possibility to organize the particles 
system along the vector of coagulative forces 
(which takes place in solutions of polymers) and 
transformation from semisolid into semiliquid 
state of matter in gels (e.g. in sol). 
The two terms chronothixotropy and mobi-
lothixotropy could help to describe this phenom-
enon more precisely. Chronothixotropy means the 
speed in which the internal structure of the liquid 
is disintegrated with stable speed of coagulation. 
The measure of structural disintegration of liquid 
under increasing speed of coagulation is mobi-
lothixotropy. The structure of liquid, including 
thixotropic ones, is characterized by some degree 
of stiffness. Disintegration of that structure relies 
on the speed of destruction of the interactions. 
The rebuilding of those interactions could lead do 
restoration. The stable state achievement is pos-
sible when the disintegration as well as building 
of new intermolecular interaction speeds are the 
same. The stiffness of the fluid is described by 
the force of maximum tension which is needed 
to total disintegration of internal structure of 
suspension previously in rest and is called the 
floating limit of thixotropic fluid.
The time needed to disintegration as well 
as restoration of internal structure of fluid is not 
stable. The rheological properties of the fluid 
change with duration of time, leading to „aging” 
of the solution. These changes are irreversible 
and connected with increasing of stiffness and 
viscosity of the liquid. The particles of the liquid 
start to form smaller conglomerates and some of 
them undergo sedimentation. The conformations 
of the chains of particles and force of relative 
organic joints could also be changed. 
Similarly to thixotropy, the energy of electric or 
magnetic field could alter the viscosity of some sub-
stances. [8] Thixotropy is confused with pseudoelas-
ticity, which is also based on decreasing of viscosity 
under acting of coagulative forces, but after yielding 
the substance is restored only partially and its struc-
ture remains changed irreversibly. The attention 
should be drawn to the liquids, which viscosity is 
increasing under the coagulation, and that phenome-
non is called anti-thixotropy [9]. Rheology (Gr. rhéō 
— flow, logos — science) is the field of knowledge 
exploring the relationships between deformation of 
continuous medium and triggering forces. 
Rheological properties of intranasal drugs
The topical intranasal aerosols are in the 
formulation of suspension with thixotropic prop-
erties. They are characterized by high basal vis-
cosity, which considerably diminishes sedimen-
tation speed of the drug’s particles. After acting 
of coagulative forces (blending of the contents 
of the container by shaking) the viscosity of the 
liquid decreases enabling spraying the dose on the 
nasal mucosa where the solution restores to the 
previous consistency with time. It is believed, that 
increasing viscosity of the substance deposited 
on mucosal surface could help to increase the 
adherence of the drug’s particles. Subsequently, 
prolonged duration of adherence increases the 
absorption of the active substance [1, 10].
In their study Eccleston et al. [2] evaluated 
the rheological properties of four intranasal glu-
cocorticosteroids available in the United States: 
triamcinolone acetonide, fluticasone propionate, 
mometasone furoate and beclometasone dipropi-
onate. Thixotropy phenomenon was observed in 
all analyzed substances, although its magnitude 
varied across the drugs. The decreasing of viscosity 
of the solution under coagulative forces was the 
highest in mometasone furoate (58,6 Pa ·s), and the 
lowest in beclometasone dipropionate (3,5 Pa ·s). 
The time of restoration to the basal viscosity also 
differed between drugs, ranging from 40 second 
for beclometasone dipropionate and triamcinolone 
acetonide, through 120 second fluticasone propi-
onate till up to over 240 second for mometasone 
furoate. After another test in the same conditions 
the authors concluded, that the observed changes 
have been entirely reversible (what was in line 
with the assumptions making thixotropy different 
from other, irreversible phenomenon). 
Shah et al. indicated the high level of mometa-
sone furoate deposition, especially in posterior part 
on nasal cavity, which is a typical location of many 
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abnormalities, including rhinosinusitis and polyps. 
After administration of the aqueous solution of 
mometasone furoate, radiolabelled with techne-
tium-99 (Tc99) 60% of the drug on average was 
deposited in the posterior part of the nasal cavity, 
26% in the anterior part, app. 10% was swallowed, 
and below 2% was inhaled into nasopharynx and 
lungs. During 15 minutes the radioactivity of de-
posited drug diminished by 60%. This additionally 
confirmed the location of the drug in posterior part 
of nasal cavity, which is predominantly covered 
by multilayered ciliated epithelium with active 
mucociliary clearance. The results showed the 
differences in deposition of mometasone furoate 
compared to remaining intranasal glucocorticoste-
roids, for which the majority of the drug has been 
deposited on nasal conchae or in the middle part 
of the nasal cavity [11].
Other factors influencing the efficacy  
of intranasal drugs
Regardless of producing of the solutions with 
thixotropic properties, the prolongation of time 
of adherence to the nasal mucosa is possible due 
to addition to the intranasal drugs of mucoadhe-
sive substances. They could improve the viscos-
ity of the solution. On the the other hand these 
substances, usually polymers, are added to slow 
down the mucociliary clearance, leading to the 
drug elimination. In this regard, one of the most 
investigated substance is chitosan. This polysac-
charide is the product of deacetylation of chitin 
from crustaceans’ carapace. Chitosan improves the 
adhesion of different substances to the mucus and 
facilitates opening of membrane channels, which 
enables the migration of polarized particles of 
the drug. Furthermore, it is non-toxic and do not 
irritate the mucosa [4]. Hyaluronic acid and hud-
roxyethylcellulose have similar properties. Thio-
glycolate chitosan, chitosan-4-thio-butyl-amidine 
(chitosan-TBA) and carboxymethylcellulose-poly-
carbophil cysteamine conjugates constitute the 
newest generation of mucoadhesive polymers. 
The increasing of mucoadhesion and subse-
quent prolongation of duration of contact of the 
drug with nasal mucosa seems to be of particular 
importance for drug used in the disorders of nasal 
mucosa itself (e.g. glucocorticoids or adrenomimet-
ics). Of note, the particles of different drugs could 
require varied modifications. For example the im-
provement of budesonide adhesion is possible due 
to formation of new fatty acid esters, while for flut-
icasone propionate this improvement is reached by 
increasing of molecular lipophilicity. Nakamura et 
al. revealed, that conjunction of budesonide with 
methacrylic acid and polyethylene glycol (MAA-
g-EG) in one co-polymer resulted in relatively fast 
absorption of the drug (Tmax 45 min.) and stable 
state lasting more than 8 hours according to the 
continuous releasing of the drug. It was possible 
due to the fact, that polymer with carboxyl groups 
strongly adhered to the mucosal epithelium as 
a results of forming of hydrogen bonds in the 
environment of pH <5, in which carboxylic acid 
does not dissociate. Resembling conjunction with 
xylomethazoline produced very similar effects.
Cytoadhesion, e.g. direct adhesion to the 
cells of mucosal epithelium is another factor 
prolonging the active drugs time of action in the 
nasal cavity. Lectins and natural glycoproteins 
show these properties, and this phenomenon was 
described by Naisbett and Woodley and Lehr. Un-
fortunately, the possible ability of lectins to trigger 
toxic reactions (e.g. lectins which is derived from 
castor oil plant Ricinus communis) entail the need 
of searching for other substances of similar mode 
of action but more favorable safety profile [1].
Table 1. Indications for intranasal administration of glucocorticosteroids [12, 13]
Indications for intranasal administration of glucocorticosteroids
— moderate-severe acute sinusitis  
— seasonal and perennial allergic rhinitis
— chronic nonallergic rhinitis
— polyps of the nose
— prevention of recurrence of polyps of nose after polypectomy
Off-label indications
— medicamental rhinitis (rhinitis medicamentosa) induced by overuse of topical drugs constricting nasal mucosa vessels
— rhinitis induced by nonsteroidal anti-inflammatory drugs (NSAIDs) intolerance
— chronic sinusitis without polyps
— upper airways cough syndrome (UACS); cough induced by post-nasal drip syndrome
— nonallergic rhinitis with eosinophilia (NARES) 
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Table 2.  Comparison of action of intranasal glicocorticosteroids with other drugs used in the treatment of allergic rhinitis [13]
Runny nose Blocked nose Sneezing Itching Ocular symptoms
Intranasal glucocorticosteroids +++ +++ +++ +++ ++
Oral antihistamine drugs ++ + ++ ++ ++
Intranasal antihistamine drugs ++ + ++ ++ 0
A-mimetics 0 ++++ 0 0 0
Cholinolytics ++ 0 0 0 0
Chromones + + + + 0
Intranasal administration of glucocorticosteroids
Topical glucocorticosteroids have an an-
ti-swelling, anti-inflammatory and anti-allergic 
activity and applied intranasally (Table 1) reas-
sure adequately high concentration of the drug 
at the site of inflammation as well as fast onset 
of action [11]. On the molecular level the drug 
binds to the glucocorticoid receptor (GR) in cell 
cytoplasm and then is transferred to the nucle-
us, where inhibits the expression of many genes 
involved in the production of proinflammatory 
cytokines. Additionally, intranasal glucocorti-
costeroids decrease the expression of adhesive 
molecules, enhance apoptosis in eosinophils, 
decrease mucus production, plug formation, 
constrict the blood vessels, reduce exudate, and 
mucosal edema (Table 2).
According to the Polish Standards of Treatment 
of Rhinitis (Polskie Standardy Leczenia Nieżytów 
Nosa, PoSLeNN) [13] intranasal glucocortico-
steroids are the backbone therapy for all forms 
of chronic allergic rhinitis as well as moderate- 
-to-severe seasonal allergic rhinitis, especially 
with nasal airway obstruction and common clin-
ical symptoms. ARIA 2010 (Allergic Rhinitis and 
its Impact on Asthma) consensus [14] suggests the 
usage of intranasal glucocorticosteroids instead of 
antihistaminic drugs in the treatment of seasonal 
and perennial allergic rhinitis in adults and in 
children. In some patients with allergic rhinitis 
and concomitant pollen sensitivity and asthma 
the intranasal glucocorticosteroids reduce the 
symptoms of asthma and non-specific overactivity 
of bronchial tree during pollen period. Some of 
the intranasal glucocorticosteroids (mometasone 
furoate, fluticasone furoate) significantly reduce 
the ocular symptoms accompanying allergic 
rhinitis. The intranasal glucocorticosteroids 
start their activity app. 7−12 hours after admin-
istration, but it should be remembered, that full 
activity is developed just after few days. So it is 
worth to start the therapy with intranasal gluco-
corticosteroids at least 10−14 days before pollen 
season and keep continuously throughout the 
whole period of allergen exposure.
The glucocorticosteroids used topically on 
nasal mucosa are characterized by low bioavail-
ability bioavailability, and thus they have not 
been demonstrated to suppress the hypothalam-
ic–pituitary–adrenal axis, especially growth and 
bone mass. This is of special importance in the 
youngest children. The most common side-effects 
of intranasal glucocorticosteroids include epi-
staxis and dryness of nasal mucosa, although the 
frequency of these symptoms is lower in patients 
correctly taking the medication. The patient 
should be informed that the end of applicator 
should be directed on the lateral wall of nasal 
cavity instead of the septum. The frequency of 
other side-effects (sneezing, stinging in nose, 
scratching in throat etc.) is comparable with 
placebo. Neither injury of epithelium nor atro-
phy of nasal mucosa was observed in patients 
systematically taking intranasal glucocortico-
steroids, even for many years. Similarly, no 
systemic side-effects have been reported, which 
are typical for systemic steroids. 
Pregnant women and children are among 
special group of patients. It should be underlined, 
that budesonide and beclomethasone are the saf-
est drugs among intranasal glucocorticosteroids 
for pregnant women (category B by Food and Drug 
Administration). In children mometasone could be 
administered the earliest e.g. after 3 years of age. 
Fluticasone propionate is registered in children 
after 4 years of age, and fluticasone furoate and 
budesonide after 6 years of age [13].
Penagos et al. in the metaanalysis of 16 ran-
domized, double-blinded clinical trials investigat-
ed the effectiveness of intranasal glucocortico-
steroids in the treatment of allergic rhinitis with 
regard to mometasone furoate. All included trials 
indicated statistically significant effectiveness 
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(level Ia by Evidence Based Medicine) of mometa-
sone taken in the nose of 100, 200, 400 and 800 µg 
once a day in reducing symptoms of seasonal and 
chronic allergic rhinitis. As compared with oral 
and intranasal antihistaminic drugs intranasal 
glucocorticosteroids showed significant advan-
tage in reducing the symptoms including nose 
obstruction and sneezing. Interestingly, there 
were no differences in alleviating of ocular symp-
toms of allergy and cough accompanying rhinitis. 
By contrast, the intranasal glucocorticosteroid 
administered as add-on therapy to antihistaminic 
drug helped to additionally reduce the symptoms 
of allergic rhinitis. The number of side-effects 
associated with usage of intranasal glucocorti-
costeroids was comparable to placebo [15]. In 
a multicenter, randomized, double-blinded clin-
ical trial Kuna et al. indicated the equivalence 
of two mometasone preparations (original and 
generic) in effective reducing of nasal and ocular 
symptoms of allergic rhinitis, with good tolerance 
and without any serious side-effects [16].
Conclusions
The topical drugs administered on nasal 
mucosa have already established in therapy. In 
diseases, such as allergic rhinitis or sinusitis, they 
are first line drugs of choice due to their topical 
action in the site of inflammation. They also could 
be a valuable alternative considering faster action 
compared to other administration routes, for 
example apomorphine in the treatment of on-off 
effect in patients with Parkinson disease. Previous 
experience enabled the development of the drugs 
with the high absorption rate and the most opti-
mal physicochemical properties. The deposition 
of the drug on nasal mucosa was optimized due 
to thixotropy phenomenon. Decreasing of viscos-
ity after shaking the solution facilitates effective 
application of aerosol dose. Subsequently, due to 
“liquid memory” the viscosity of the drug restores, 
to favor adhesion to nasal mucosa and additional 
mucoadhesive molecules could be very helpful. 
The further investigations are focused on 
searching for new substances acting not only topi-
cally but systemically, which could be administered 
intranasally after possible modification of the mole-
cule as well as developing of additional substances 
improving the absorption. They are sometimes 
pioneering in nature, similarly to development of 
intranasal insulin, which was finally withdrawn 
from the market for additional research.
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